IGM Biosciences, Inc.

Overview

• IndustryPharmaceutical Preparations²
• HeadquartersMountain View, United States²
• Incorporated inDE⁴
• Business address325 E Middlefield Road, Mountain View, Ca 94043⁴
• Filer categoryNon-accelerated filer, Smaller reporting company⁴
• Legal formCorporation²
• LEI5493008XCQES2N0VY969²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 2348788²

See how the biggest companies compare on our leaderboards

We are a biotechnology company that has historically been focused on the development of IgM antibodies for the treatment of cancer and autoimmune and inflammatory diseases. IgM antibodies have inherent properties that we believe may enable them to bind more strongly to targets on the surface of cells than comparable IgG antibodies.⁵ From its latest annual report

Corporate structure

IGM Biosciences, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What IGM Biosciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

We lease approximately 95,900 square feet of office, laboratory and manufacturing space in Mountain View, California and office and laboratory space in Doylestown, PA. These leases have expiration dates ranging from December 2025 through June 2032. We believe that our facilities are adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional space will be available on commercially reasonable terms to accommodate any such expansion of our operations.

Item 2 of the 10-K filed Mar 6, 2025.⁵

Leadership

Who has led IGM Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerMary Beth Harler Oct 4, 2024 to now¹⁵
• Chief executive officerFred Schwarzer Sep 17, 2019 to Oct 4, 2024¹⁶
• PresidentFred Schwarzer Sep 17, 2019 to now¹⁶
• Chief financial officerMisbah Tahir Sep 17, 2019 to now¹⁷

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerLisa L. Decker named Jul 7, 2023³¹
• DirectorMichael J. Lee named Jul 7, 2023³¹

Former names

• Palingen, Inc.Jul 16, 2010 to Jul 16, 2010⁴

Timeline

1. Aug 14, 20258-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights³²
2. Jul 1, 20258-K Entered a material agreement; Executive or director change; Regulation FD disclosure³³
3. Jun 11, 20258-K Listing notice or transfer³⁴
4. May 29, 20258-K Entered a material agreement; Ended a material agreement³⁵
5. May 8, 20258-K Ended a material agreement; Regulation FD disclosure³⁶
6. Mar 6, 20258-K Exit or restructuring costs³⁷
7. Jan 10, 20258-K Results of operations; Exit or restructuring costs; Regulation FD disclosure³⁸
8. Nov 8, 20248-K Exit or restructuring costs³⁹
9. Nov 8, 20248-K Results of operations⁴⁰
10. Oct 4, 2024New chief executive Mary Beth Harler becomes CEO¹⁵
11. Oct 3, 20248-K Exit or restructuring costs; Executive or director change⁴¹
12. Aug 14, 20248-K Results of operations⁴²
13. Jul 5, 20248-K Regulation FD disclosure⁴³
14. Sep 17, 2019New chief executive Fred Schwarzer becomes CEO¹⁶
15. Aug 25, 1993Founded IGM Biosciences, Inc. is founded²

Calendar

When it reported results

1. Jan 10, 2025Reported quarterly or annual results³⁸
2. Nov 8, 2024Reported quarterly or annual results⁴⁰
3. Aug 14, 2024Reported quarterly or annual results⁴²
4. May 8, 2024Reported quarterly or annual results⁴⁴
5. Mar 7, 2024Reported quarterly or annual results⁴⁵
6. Jan 8, 2024Reported quarterly or annual results⁴⁶
7. Nov 13, 2023Reported quarterly or annual results⁴⁷
8. Aug 3, 2023Reported quarterly or annual results⁴⁸

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

469 filings to the SEC since October 2021: 5 annual reports, 12 quarterly reports, 39 major events, 311 insider forms, 27 large holders, 1 private raises, 74 other. The latest 20:

1. Nov 13, 2025SCHEDULE 13G/A EDGAR
2. Aug 25, 202515-12G EDGAR
3. Aug 18, 2025SCHEDULE 13D/A EDGAR
4. Aug 18, 20254 EDGAR
5. Aug 18, 2025SCHEDULE 13D/A EDGAR
6. Aug 15, 2025SCHEDULE 13D/A EDGAR
7. Aug 15, 20254 OWNERSHIP DOCUMENT EDGAR
8. Aug 14, 2025EFFECT EDGAR
9. Aug 14, 2025EFFECT EDGAR
10. Aug 14, 2025EFFECT EDGAR
11. Aug 14, 2025EFFECT EDGAR
12. Aug 14, 2025EFFECT EDGAR
13. Aug 14, 20254 EDGAR
14. Aug 14, 20254 EDGAR
15. Aug 14, 20254 EDGAR
16. Aug 14, 20254 EDGAR
17. Aug 14, 20254 EDGAR
18. Aug 14, 20254 EDGAR
19. Aug 14, 20254 EDGAR
20. Aug 14, 20254 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

120 open-market trades by officers, directors and large owners since October 2021: 22 buys and 98 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• GLAZER CAPITAL, LLCSCHEDULE 13G/A, 2 filings Jul 9, 2025 to Nov 13, 2025⁴⁹
• BAKER BROS. ADVISORS LPSCHEDULE 13D/A, 5 filings Apr 5, 2022 to Aug 18, 2025⁵⁰
• Topsoe Holding A/SSCHEDULE 13D/A, 2 filings Jul 19, 2023 to Aug 18, 2025⁵¹
• Redmile Group, LLCSCHEDULE 13D/A, 5 filings Apr 5, 2022 to Aug 15, 2025⁵²
• PRICE T ROWE ASSOCIATES INC /MD/SCHEDULE 13G/A, 7 filings Feb 14, 2022 to Feb 14, 2025⁵³
• FMR LLCSC 13G/A, 2 filings Feb 9, 2024 to Nov 12, 2024⁵⁴
• Invus Global Management, LLCSC 13G/A, 1 filing Aug 2, 2024⁵⁵
• Artal International S.C.A.SC 13G/A, 3 filings Feb 11, 2022 to Feb 9, 2024⁵⁶

Money raised

Private offerings the company reported to the SEC on Form D.

1. Jun 26, 2023Raised $22.5 million in a private offering of equity Form D: 1 investor so far Form D

SEC filer profile

How IGM Biosciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARIGM Biosciences, Inc.¹
• CIK0001496323
• Employer ID (EIN)77-0349194⁵
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁵
• Incorporated inDelaware⁵
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address325 E Middlefield Road, Mountain View, CA 94043¹
• Phone650-965-7873¹
• Shares outstanding34,388,419 Common Stock shares; 25,386,983 Nonvoting Common Stock shares as of Feb 28, 2025⁵
• Public float$50.7M as of Jun 28, 2024⁵
• AuditorDeloitte & Touche LLP, San Francisco, California PCAOB ID 34; no auditor attestation of internal control over financial reporting⁵
• On EDGAR sinceJul 16, 2010¹
• Filings710 in all: 4 (448), 8-K (55), 3 (21), 10-Q (18), SC 13D/A (15), 144 (14), EFFECT (11), SC 13G/A (11)¹
  All 50 form types

  CORRESP (8), S-8 (8), S-8 POS (8), UPLOAD (8), 10-K (6), 424B5 (6), DEF 14A (6), POS AM (5), S-3 (5), DEFA14A (4), SC 13G (4), 4/A (3), FWP (3), PRE 14A (3), SC 13D (3), SC TO-I/A (3), SCHEDULE 13D/A (3), SCHEDULE 13G/A (3), 8-K/A (2), ARS (2), D (2), S-1/A (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 3/A (1), 424B3 (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), S-1 (1), SC 14D9 (1), SC 14D9/A (1), SC TO-C (1), SC TO-I (1), SC TO-T (1), SC TO-T/A (1), SC14D9C (1), SCHEDULE 13G (1)

• Latest filingsAnnual report (10-K) Mar 6, 2025
  Quarterly report (10-Q) Jul 31, 2025
  Proxy statement (DEF 14A) Apr 26, 2024
  Latest 8-K (8-K) Aug 14, 2025

Securities registered for trading

From the cover page of the 10-K filed Mar 6, 2025 (Section 12(b) of the Exchange Act).⁵

Risk factors and legal proceedings

The risks IGM Biosciences, Inc. names in Item 1A of its 10-K filed Mar 6, 2025: 75 risks under these headings, as written.⁵

• Unless the context otherwise requires, any references to or discussion of "product candidates" in these Risk Factors refer to the IgM antibodies we are developing under the Sanofi Agreement or any product candidates that we may otherwise pursue in the future, if any. Further, unless the context otherwise requires, any references to or discussion of "clinical trials" or "clinical development" in these Risk Factors refer to any such clinical trials or clinical development that we may in the future conduct in connection with the Sanofi Agreement or may otherwise pursue in the future, if any.
• Risks Related to Our Business and the Development and Commercialization of Our Product Candidates
• Our only ongoing IgM-related efforts relate to the targets we are developing under the Sanofi Agreement, and we have not completed the development of any product candidates. If we are unable to discover and develop product candidates, advance product candidates through clinical development, obtain regulatory approval and commercialize one or more of our product candidates, our business will be materially adversely affected and we may never generate any product revenue.
• Our activities to evaluate and pursue potential strategic alternatives may not result in any definitive transaction or enhance stockholder value.
• If we fail to achieve the expected financial and operational benefits of our recent cash preservation activities, our business and financial results may be harmed.
• The use of engineered IgM antibodies is a novel and unproven therapeutic approach and our discovery and research programs may never lead to a marketable product.
• Following the 2025 Restructuring, we may decide not to develop product candidates through the IgM platform outside of the Sanofi Agreement. If, in the future, we do pursue such product candidates, we may not be successful in our efforts.
• In the future we may seek approval from the FDA or comparable foreign regulatory authorities through the use of expedited approval pathways, such as Fast Track designation and Breakthrough Therapy designation, orphan drug designation, or accelerated approval. Even if we receive accelerated approval from the FDA or comparable regulatory authorities, if our confirmatory clinical trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA or such other regulatory authorities may seek to withdraw accelerated approval.
• Product candidates we may develop may have undesirable side effects that may delay or prevent marketing approval or, if approval is received, require them to be taken off the market, require them to include new safety warnings, contraindications or precautions, or otherwise limit their sales. No regulatory agency has made a determination that any of our product candidates are safe or effective for use by the general public for any indication.
• We face significant competition from entities that have developed or may develop product candidates for the treatment of diseases that we are initially targeting, including companies developing novel treatments and technology platforms. If our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.
• We and our third-party manufacturers have encountered and may continue to encounter difficulties in the production of product candidates, and supply chain shortages have limited and may continue to limit access to raw materials and other supplies. Should we encounter any such difficulties, our ability to manufacture drug substance or supply our product candidates for preclinical studies or future clinical trials or, if approved, for commercial sale, could be further delayed or halted entirely.
• We may expend our limited resources to pursue product candidates or indications that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Legal proceedings

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.

The opening of Item 3, Legal Proceedings.⁵